T2*-weighted image/T2-weighted image fusion in postimplant dosimetry of prostate brachytherapy

Norihisa Katayama, Mitsuhiro Takemoto, Kotaro Yoshio, Kuniaki Katsui, Tatsuya Uesugi, Yasutomo Nasu, Toshi Matsushita, Mitsumasa Kaji, Hiromi Kumon, Susumu Kanazawa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Computed tomography (CT)/magnetic resonance imaging (MRI) fusion is considered to be the best method for postimplant dosimetry of permanent prostate brachytherapy; however, it is inconvenient and costly. In T2*-weighted image (T2*-WI), seeds can be easily detected without the use of an intravenous contrast material. We present a novel method for postimplant dosimetry using T2*-WI/T2-weighted image (T2-WI) fusion. We compared the outcomes of T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based postimplant dosimetry. Between April 2008 and July 2009, 50 consecutive prostate cancer patients underwent brachytherapy. All the patients were treated with 144 Gy of brachytherapy alone. Dose-volume histogram (DVH) parameters (prostate D90, prostate V100, prostate V150, urethral D10, and rectal D2cc) were prospectively compared between T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based dosimetry. All the DVH parameters estimated by T2*-WI/T2-WI fusion-based dosimetry strongly correlated to those estimated by CT/T2-WI fusion-based dosimetry (0.77 ≤ R ≤ 0.91). No significant difference was observed in these parameters between the two methods, except for prostate V150 (p = 0.04). These results show that T2*-WI/T2-WI fusion-based dosimetry is comparable or superior to MRI-based dosimetry as previously reported, because no intravenous contrast material is required. For some patients, rather large differences were observed in the value between the 2 methods. We thought these large differences were a result of seed miscounts in T2*-WI and shifts in fusion. Improving the image quality of T2*-WI and the image acquisition speed of T2*-WI and T2-WI may decrease seed miscounts and fusion shifts. Therefore, in the future, T2*-WI/T2-WI fusion may be more useful for postimplant dosimetry of prostate brachytherapy.

Original languageEnglish
Pages (from-to)680-684
Number of pages5
JournalJournal of Radiation Research
Volume52
Issue number5
DOIs
Publication statusPublished - 2011

Fingerprint

Brachytherapy
dosimeters
Prostate
fusion
Tomography
Seeds
Contrast Media
Magnetic Resonance Imaging
Prostatic Neoplasms
tomography
seeds
histograms
magnetic resonance
dosage

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Health, Toxicology and Mutagenesis

Cite this

T2*-weighted image/T2-weighted image fusion in postimplant dosimetry of prostate brachytherapy. / Katayama, Norihisa; Takemoto, Mitsuhiro; Yoshio, Kotaro; Katsui, Kuniaki; Uesugi, Tatsuya; Nasu, Yasutomo; Matsushita, Toshi; Kaji, Mitsumasa; Kumon, Hiromi; Kanazawa, Susumu.

In: Journal of Radiation Research, Vol. 52, No. 5, 2011, p. 680-684.

Research output: Contribution to journalArticle

Katayama, Norihisa ; Takemoto, Mitsuhiro ; Yoshio, Kotaro ; Katsui, Kuniaki ; Uesugi, Tatsuya ; Nasu, Yasutomo ; Matsushita, Toshi ; Kaji, Mitsumasa ; Kumon, Hiromi ; Kanazawa, Susumu. / T2*-weighted image/T2-weighted image fusion in postimplant dosimetry of prostate brachytherapy. In: Journal of Radiation Research. 2011 ; Vol. 52, No. 5. pp. 680-684.
@article{9d44633a7f5e40f5a9df51f0e00a8704,
title = "T2*-weighted image/T2-weighted image fusion in postimplant dosimetry of prostate brachytherapy",
abstract = "Computed tomography (CT)/magnetic resonance imaging (MRI) fusion is considered to be the best method for postimplant dosimetry of permanent prostate brachytherapy; however, it is inconvenient and costly. In T2*-weighted image (T2*-WI), seeds can be easily detected without the use of an intravenous contrast material. We present a novel method for postimplant dosimetry using T2*-WI/T2-weighted image (T2-WI) fusion. We compared the outcomes of T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based postimplant dosimetry. Between April 2008 and July 2009, 50 consecutive prostate cancer patients underwent brachytherapy. All the patients were treated with 144 Gy of brachytherapy alone. Dose-volume histogram (DVH) parameters (prostate D90, prostate V100, prostate V150, urethral D10, and rectal D2cc) were prospectively compared between T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based dosimetry. All the DVH parameters estimated by T2*-WI/T2-WI fusion-based dosimetry strongly correlated to those estimated by CT/T2-WI fusion-based dosimetry (0.77 ≤ R ≤ 0.91). No significant difference was observed in these parameters between the two methods, except for prostate V150 (p = 0.04). These results show that T2*-WI/T2-WI fusion-based dosimetry is comparable or superior to MRI-based dosimetry as previously reported, because no intravenous contrast material is required. For some patients, rather large differences were observed in the value between the 2 methods. We thought these large differences were a result of seed miscounts in T2*-WI and shifts in fusion. Improving the image quality of T2*-WI and the image acquisition speed of T2*-WI and T2-WI may decrease seed miscounts and fusion shifts. Therefore, in the future, T2*-WI/T2-WI fusion may be more useful for postimplant dosimetry of prostate brachytherapy.",
author = "Norihisa Katayama and Mitsuhiro Takemoto and Kotaro Yoshio and Kuniaki Katsui and Tatsuya Uesugi and Yasutomo Nasu and Toshi Matsushita and Mitsumasa Kaji and Hiromi Kumon and Susumu Kanazawa",
year = "2011",
doi = "10.1269/jrr.11011",
language = "English",
volume = "52",
pages = "680--684",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Japan Radiation Research Society",
number = "5",

}

TY - JOUR

T1 - T2*-weighted image/T2-weighted image fusion in postimplant dosimetry of prostate brachytherapy

AU - Katayama, Norihisa

AU - Takemoto, Mitsuhiro

AU - Yoshio, Kotaro

AU - Katsui, Kuniaki

AU - Uesugi, Tatsuya

AU - Nasu, Yasutomo

AU - Matsushita, Toshi

AU - Kaji, Mitsumasa

AU - Kumon, Hiromi

AU - Kanazawa, Susumu

PY - 2011

Y1 - 2011

N2 - Computed tomography (CT)/magnetic resonance imaging (MRI) fusion is considered to be the best method for postimplant dosimetry of permanent prostate brachytherapy; however, it is inconvenient and costly. In T2*-weighted image (T2*-WI), seeds can be easily detected without the use of an intravenous contrast material. We present a novel method for postimplant dosimetry using T2*-WI/T2-weighted image (T2-WI) fusion. We compared the outcomes of T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based postimplant dosimetry. Between April 2008 and July 2009, 50 consecutive prostate cancer patients underwent brachytherapy. All the patients were treated with 144 Gy of brachytherapy alone. Dose-volume histogram (DVH) parameters (prostate D90, prostate V100, prostate V150, urethral D10, and rectal D2cc) were prospectively compared between T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based dosimetry. All the DVH parameters estimated by T2*-WI/T2-WI fusion-based dosimetry strongly correlated to those estimated by CT/T2-WI fusion-based dosimetry (0.77 ≤ R ≤ 0.91). No significant difference was observed in these parameters between the two methods, except for prostate V150 (p = 0.04). These results show that T2*-WI/T2-WI fusion-based dosimetry is comparable or superior to MRI-based dosimetry as previously reported, because no intravenous contrast material is required. For some patients, rather large differences were observed in the value between the 2 methods. We thought these large differences were a result of seed miscounts in T2*-WI and shifts in fusion. Improving the image quality of T2*-WI and the image acquisition speed of T2*-WI and T2-WI may decrease seed miscounts and fusion shifts. Therefore, in the future, T2*-WI/T2-WI fusion may be more useful for postimplant dosimetry of prostate brachytherapy.

AB - Computed tomography (CT)/magnetic resonance imaging (MRI) fusion is considered to be the best method for postimplant dosimetry of permanent prostate brachytherapy; however, it is inconvenient and costly. In T2*-weighted image (T2*-WI), seeds can be easily detected without the use of an intravenous contrast material. We present a novel method for postimplant dosimetry using T2*-WI/T2-weighted image (T2-WI) fusion. We compared the outcomes of T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based postimplant dosimetry. Between April 2008 and July 2009, 50 consecutive prostate cancer patients underwent brachytherapy. All the patients were treated with 144 Gy of brachytherapy alone. Dose-volume histogram (DVH) parameters (prostate D90, prostate V100, prostate V150, urethral D10, and rectal D2cc) were prospectively compared between T2*-WI/T2-WI fusion-based and CT/T2-WI fusion-based dosimetry. All the DVH parameters estimated by T2*-WI/T2-WI fusion-based dosimetry strongly correlated to those estimated by CT/T2-WI fusion-based dosimetry (0.77 ≤ R ≤ 0.91). No significant difference was observed in these parameters between the two methods, except for prostate V150 (p = 0.04). These results show that T2*-WI/T2-WI fusion-based dosimetry is comparable or superior to MRI-based dosimetry as previously reported, because no intravenous contrast material is required. For some patients, rather large differences were observed in the value between the 2 methods. We thought these large differences were a result of seed miscounts in T2*-WI and shifts in fusion. Improving the image quality of T2*-WI and the image acquisition speed of T2*-WI and T2-WI may decrease seed miscounts and fusion shifts. Therefore, in the future, T2*-WI/T2-WI fusion may be more useful for postimplant dosimetry of prostate brachytherapy.

UR - http://www.scopus.com/inward/record.url?scp=80053360724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053360724&partnerID=8YFLogxK

U2 - 10.1269/jrr.11011

DO - 10.1269/jrr.11011

M3 - Article

C2 - 21857148

AN - SCOPUS:80053360724

VL - 52

SP - 680

EP - 684

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 5

ER -